Drug intelligence / Profile preview

SVV-044

Development stage: Preclinical
Lead developer: Seneca Therapeutics
Modality: Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
Administration: Intravenous

Overview

SVV-044 is a preclinical **armed oncolytic virus therapy** being developed by Seneca Therapeutics for cancer. It is based on **Seneca Valley Virus**, specifically the SVV-001 platform, and has been genetically engineered to express a **transforming growth factor beta decoy receptor** intended to sequester TGF-beta in the tumor microenvironment and reduce tumor-associated immunosuppression. The construct is designed to retain the native tumor tropism of Seneca Valley Virus for **tumor endothelial marker 8** expressing cancer cells while adding local immunomodulatory gene-delivery functionality. Available descriptions indicate planned **intravenous** development for neoplasms, with the program reported in the **preclinical** stage.

Other names: Seneca Valley Virus armed with a TGF-beta decoy receptor

Targets

ANTXR1 (Anthrax toxin receptor 1)Transforming growth factor beta (TGF-beta) signaling pathway

Beyond the preview

Go deeper on SVV-044.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SVV-044.

Explore the full profile